Lansing, Michigan – Ionetix Corporation is pleased to announce the official project start to expand its Alpha Isotope Manufacturing facility. This project marks a significant milestone for Ionetix in establishing a robust supply platform that includes onsite redundancy of Ac-225 production, as well as scalable output capacity to support commercial activity.

Ionetix’s Alpha Isotope Manufacturing Facility, located in Lansing, Michigan, is a first of its kind commercial facility dedicated exclusively to the production of alpha-emitting radionuclides which are being used to develop new highly targeted cancer therapeutics.   The expansion project will add over 5,000 sq/ft of additional space to the existing building. The new addition will house a second cyclotron and additional isotope processing lab equipment and infrastructure. The new cyclotron will have dual target stations and utilize Ionetix’s proprietary cyclotron target technology for Ac-225 production. Once completed, the new cyclotron, using the multiple target stations, will allow for continuous isotope production that can scale to more than 1 Curie of Ac-225 per week.

“We are thrilled to get this project started,” said David Eve, VP of Medical Affairs at Ionetix. “Moving forward with the second cyclotron reflects our commitment to our pharmaceutical partners, drug developers, and researchers to make sure that Ac-225 is readily available to support unfettered patient access to these new and promising cancer-fighting therapeutics.”

Construction is expected to run through the first half of 2025 and work will be isolated from the existing facility.  Existing operations will not be impacted, allowing production and distribution of alpha isotopes to continue uninterrupted.

About IONETIX
Utilizing its proprietary cyclotron technology platform, IONETIX has developed innovative solutions that enable access to scarce radioisotopes used for both diagnostic and therapeutic radiopharmaceuticals. IONETIX offers both high-purity Actinium-225 (Ac-225) and Astatine-211 (At-211) for use in targeted alpha therapies. IONETIX also provides N-13, F-18 and Ga-68 for diagnostic imaging. Its distribution supply chain includes contract drug manufacturing and “white glove” distribution logistics, allowing global access to these imaging agents and targeted radiotherapies. Contact us for more information.